Autolus enters $250 million senior secured notes facility with Perceptive
Autolus Therapeutics signed a Note Purchase Agreement on July 30, 2026, for a senior secured notes facility of up to $250.0 million, with $75.0 million issued at closing. The company also issued Perceptive a warrant for up to 3,500,000 ADSs, which adds potential future share dilution, and agreed to file a resale registration statement within 45 calendar days of closing.
Key points
- Tranche 1 notes of $75.0 million issued July 30, 2026; up to $175.0 million more available in three tranches
- Interest is a margin of 6.75% to 7.25% plus the greater of one-month term SOFR and 3.50%; maturity July 30, 2031
- Warrant for up to 3,500,000 ADSs at $1.9314 per ADS, expiring July 30, 2036; notes are secured by substantially all company and subsidiary assets
- Financial covenants require minimum liquidity of $12.5 million to $50.0 million and minimum Consolidated Net Revenue
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.